Business Trip

In today’s episode, we explore the therapeutic application of DMT across a range of diseases and conditions including Alzheimer’s, stroke, and organ transplants. While much of the attention in psychedelic medicine has been on their ability to address neuropsychiatric indications, research suggests that psychedelics like DMT have a far wider therapeutic potential. The episode features three biotech companies developing DMT therapies:  Algernon, Psilera, and Pharmadrug.

In this episode, we discuss:

• DMT therapies for organ transplants, stroke patients and substance abuse disorders
• Research supporting NN-DMT’s antioxidative and anti-inflammatory effects and the receptors it targets
• Being a private company vs. public company in psychedelics

NN-DMT
5-MeO-DMT
Bioavailability
DMT transdermal patch
Sigma-1
Donepezil
Dr. Rick Strassman
Angiogenesis
Orphan Drug Designation

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky
Produced by Jonathan A. Davis & Zack Frank
Marketing by DaisyMae VanValkenburgh

Read the transcript here.

Find us at businesstrip.fm
Follow us on Instagram and Twitter!

Theme music by Dorian Love
Additional music: Copley Beat by Blue Dot Sessions, Simplify by Little Glass Men, Pedalrider by Blue Dot Sessions, Running Waters by Jason Shaw, and Neon Drip by Blue Dot Sessions

Episode 10 features Lars Wilde, co-founder and Chief Business Officer of Compass Pathways, a mental health company with an initial focus on psilocybin therapy for Treatment-Resistant Depression.

In this episode, we discuss:

• Lars’ experience overcoming Treatment-Resistant Depression with psilocybin
• The nuances of clinical trials and psilocybin dosing protocols
• Compass Pathways’ Intellectual Property strategy
• What additional indications and therapies Compass Pathways is interested in

Links to topics discussed in this episode:
Compass Pathways, Lars Wilde
COMP360
SSRI, SNRI
Christian Angermayer, Robin Carhart-Harris, Michael Pollan
Vivaneo
Quercis Pharma
TRD (Therapy-Resistant Depression)
Compass Phase 2B Trial
Jazz Pharmaceuticals
Compass Pathways 2 US patents
Oregon Psilocybin Therapy Measure 109

Read the transcript here.
Watch episode 10 on YouTube.

Created by Greg Kubin and Matias Serebrinsky
Hosts: Matias Serebrinsky and Greg Kubin
Produced by Jonathan A. Davis & Zack Frank
Marketing by DaisyMae VanValkenburgh

Find us at businesstrip.fm
Follow us on Instagram and Twitter!

Theme music by Dorian Love
Additional music: River Meditation by Jason Shaw and Thea by Muted Circus

Today's episode features three experts, Josh Hardman, Michael Haichin, and Graham Pechenik as they analyze atai’s S-1 in advance of their IPO. 

In this episode, we discuss:

• How atai went from idea to IPO in 3 years
• An overview of atai’s drug development programs and enabling technologies
• The platform’s strategy and risks

Links to topics in this episode:
Atai life sciences
Etifoxine
Esketamine & arketamine
Atai’s S-1
Psychedelic Pharmacist Association
Calyx Law
Psilocybin Alpha, Noetic Fund
kratom, Salvinorin A, BNC210, mitragynine
Mike Novogratz, Christian Angermayer, George Goldsmith, Ekaterina Malievskaia, Peter Thiel
PureTech Health, Akili Interactive Labs
BT’s DemeRx Episode
Viridia Life Sciences, EmpathBio, Kures, Recognify Life Sciences

Read the transcript here.
Watch episode 9 on YouTube.
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky
Produced by Jonathan A. Davis & Zack Frank
Marketing by DaisyMae VanValkenburgh

Find us at businesstrip.fm
Follow us on Instagram and Twitter!

Theme music by

Today's episode features Deborah Mash, founder and CEO of DemeRx, a clinical stage company developing ibogaine therapies to treat substance use disorders.

In this episode, we discuss:

• The science, experience and the safety behind Ibogaine’s “neurochemical reset”
• Navigating US drug regulatory system and securing Intellectual Property
• Deborah’s 30 journey through Amsterdam, Miami and the Caribbean aiming to get Ibogaine therapy approved
• Partnership with ATAI Life Sciences

Links to topics discussed in this episode:
Deborah Mash
DemeRx
Ibogaine
Noribogaine
Tabernanthe Iboga
Bwiti Religion
Howard Lotsof
Serotonergics
Lambarene - promoted as a mental and physical stimulant
Habenula
Addiction Expert Gabor Maté

Read the transcript here.
Watch episode 8 on YouTube.
Created by Greg Kubin and Matias Serebrinsky
Host: Greg Kubin
Produced by Jonathan A. Davis & Zack Frank
Marketing by DaisyMae VanValkenburgh

Find us at businesstrip.fm
Follow us on Instagram and Twitter!

Theme music by Dorian Love
Additional music by Medita by Crowander, Two Feet by Muted Circus, and Rain On Me by JBlanked.

Today's episode features Zach Haigney, creator of The Trip Report, a newsletter about psychedelics, policy and business.

In 2019, Zach started writing The Trip Report and quickly grew his readership by analyzing psychedelic news headlines from every angle. He’s able to break through all the noise and report with a sense of fairness.

In this episode, we discuss:

• Origin story of The Trip Report
• The complexities of clinical trials
• Diversity, inclusion and reciprocity in psychedelic companies

Links to topics discussed in this episode:
The Trip Report
Zach Haigney
Oregon Measure 109 - 2020
MAPS
COMPASS Pathways
Usona
Psilocybin Alpha
Bob Jesse - Council for Spiritual Practices
5-HT2A
Serotonin Syndrome
Northstar Pledge
Nagoya Protocol
Free, Prior, and Informed Consent

Read the transcript here.
Watch episode 7 on YouTube.
Created by Greg Kubin and Matias Serebrinsky
Host: Greg Kubin
Produced by Jonathan A. Davis & Zack Frank
Marketing by DaisyMae VanValkenburgh

Find us at businesstrip.fm
Follow us on Instagram and Twitter!

Theme music by Dorian Love
Additional music by Sun Inside by Ketsa and Better Days Ahead by Ketsa

Today's episode features Danny Motyka, founder of Psygen, a Canadian manufacturer of psychedelics, like MDMA, LSD, DMT, and synthetic psilocybin.

Psygen makes pharmaceutical grade psychedelic medicines for clinical research and therapeutic applications. They have a license to be one of the first manufacturing facilities dedicated to the synthesis of psychedelic medicine. 

In this episode, we discuss:

• Behind the scenes of Psygen’s manufacturing process
• Natural vs Synthetic psychedelics
• Navigating regulations for manufacturing Schedule 1 substances

Links to topics discussed in this episode:

GMP
Dr. Peter van der Heyden
COMP360
Entourage Effect
Health Canada
Nick Sand - Orange Sunshine
MDMA, LSD, 5-MeO-DMT, Ibogaine, Psilocybin
Entheon Biomedical
MAPS
2C-B

Read the transcript here.
Watch episode 6 on YouTube.
Created by Greg Kubin and Matias Serebrinsky
Host: Greg Kubin
Produced by Jonathan A. Davis & Zack Frank
Marketing by DaisyMae VanValkenburgh

Find us at businesstrip.fm
Follow us on Instagram and Twitter!

Theme music by Dorian Love
Additional music by Crystals by Xylo-Ziko, Obscure Train by Revolution Void, Love Chances by Makaih Beats, and Kleptotonic Swing by Tri-Tachyon

Today's episode features Flor Bollini, founder of NANA, an online platform that guides patients on using psychedelic medicine for holistic healing.

NANA provides personalized protocols based on an assessment of your mental, emotional and physical health. From there you are partnered with a Nana or guide who leads telemedicine therapy that incorporates ketamine, cannabis and CBD.

Flor hopes these protocols will become best practices for patients, clinics, and the psychedelic medicine ecosystem.

In this episode, we discuss:

• Why Flor transitioned from serving medicine to company founder
• Developing protocols where the FDA doesn’t regulate
• The benefits of progressive dosing
• Her experiences with 5-MeO-DMT and Iboga. “The Everest of psychedelics” as she calls them.

Links to topics discussed in this episode:
UNESCO - United Nations Educational, Scientific and Cultural Organization
Ifa - Ancient Divination System
Ayurveda
Jungian
5-MeO-DMT
LMS - Learning Management System
REM Sleep - Rapid Eye Movement Sleep
SSRIs - Selective Serotonin Reuptake Inhibitors
Ayahuasca
Ibogaine
Bwiti religion
Serotonin Syndrome

Read the transcript here.
Watch episode 5 on YouTube.
Created by Greg Kubin and Matias Serebrinsky
Host: Greg Kubin
Produced by Jonathan A. Davis
Marketing by DaisyMae VanValkenburgh

Find us at businesstrip.fm
Follow us on Instagram and Twitter!

Theme music by Dorian Love
Additional music by Blue Dot Sessions.

Today's episode features David Champion, CEO and co-founder of Maya, a software platform that helps practitioners and clinics manage psychedelic-assisted therapy practices. The data collected from treatments will help psychedelic stakeholders, from researchers to pharmaceutical companies, discover insights for safer and more effective treatments.

In this episode, we discuss:

• Removing the guesswork from developing psychedelic therapy protocols
• Fundraising tips for psychedelic company founders
• The role of data in surfacing safer and more effective treatments
• A big announcement from Matias and Greg!

Links to topics discussed in this episode:

Zendo Project - Subsidiary of MAPS
Johns Hopkins - Center for Psychedelic and Consciousness Research
MAPS
CIIS
EMR & EHR - What's the difference?

Read the transcript here.
Watch episode 4 on YouTube.

Created by Greg Kubin and Matias Serebrinsky
Host: Greg Kubin
Produced by Jonathan A. Davis
Marketing by DaisyMae VanValkenburgh

Find us at businesstrip.fm
Follow us on Instagram and Twitter!

Theme music by Dorian Love
Additional music by Blue Dot Sessions.

Today's episode features Ryan Zurrer, founder of Vine Ventures, one of the first venture capital funds investing in psychedelic medicine. Ryan has deep roots in psychedelics culture and understands the many cultures within the psychedelic space. His fund is aligned with those values.

If you’re a founder, investor, or early hire at a psychedelic company, this episode is a must-listen!

In this episode, we discuss:

• Which psychedelic business models are a good fit for venture capital?
• Why did Ryan start Vine Ventures?
• What traits of entrepreneurs does Ryan invest in?
• Which form of psychedelic medicine is better: natural or synthetic compounds? 

Links to topics discussed in this episode:

Pharmauasca
Oregon Initiative Measure 109
ENTHEON
PsyGen
California Sober
Atai
Compass
Get in touch with Ryan Zurrer - TW: @rzurrer LI: Ryan Zurrer

Read the transcript here.

Watch episode 3 on YouTube.

Created by Greg Kubin and Matias Serebrinsky
Host: Greg Kubin
Produced by Jonathan A. Davis

Find us at businesstrip.fm
Follow us on Instagram and Twitter!

Theme music by Dorian Love
Additional music by Blue Dot Sessions and Chad Crouch

Today’s episode features Shelby Hartman and Madison Margolin from DoubleBlind, a psychedelic magazine and media company founded in 2019 covering timely, untold stories about the expansion of psychedelics around the globe. Focused on how the industry can engage in sacred reciprocity and ethical psychedelic therapies, DoubleBlind is a for-profit company working on becoming a fully licensed certified B corporation.

Links to topics discussed in this episode:
What It’s Like to Have Sex on Different Kinds of Psychedelics
How Oregon is Leading the Country in Drug Policy Reform
Entheogen: Definition and History
How Psychedelics are Reigniting Judaism
Michael Pollan's book How to Change Your Mind
Ayelet Waldman's book: A Really Good Day: How Microdosing Made a Mega Difference in My Mood, My Marriage, and My Life
MDMA Testing Kits from DanceSafe

Read the transcript here.

Watch episode 2 on YouTube.

Created by Greg Kubin and Matias Serebrinsky
Host: Greg Kubin
Produced by Jonathan A. Davis

Find us at businesstrip.fm
Follow us on Instagram and Twitter!

Theme music by Dorian Love
Additional music: Plasticity by Blue Dot Sessions


IsEbOcbXwtgQS6Jzz1Eb